U.S. Patient and Trademark. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
iling Date		
irst Named Inventor Robe		rt-Christian Hagen
Art Unit		
xaminer Name		
Attorney Docket Numb	er	I431.175.101/FIN592PCT/US

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear				
	1	6313522		2001-11-06	Akram et al.					
	2	6437433		2002-08-20	Ross					
	3 6407448 2002-06-18 Chr		Chun							
If you wis	h to a	dd additional U.S. Pater	t citatio	n information pl	ease click the Add button.	Add				
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove				
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	20010028104		2001-10-11	Fukatsu et al.					
	2	20020163077		2002-11-07	Kuwahara et al.					
	3	20030020154		2003-01-30	Hashimoto					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number | Filing Date | Filing

	4	20030030143	2003-0	2-13	Wennemuth et al.					
If you wis	h to a	dd additional U.S. Publi	shed Application	citatio	n information p	please click the Add	butto	n. Add		
			FOREIG	SN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴		Name of Patentee or Applicant of cited Document		Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	T5	
	1	DE10138278C1	DE		2003-04-03	Infineon Technologies AG				
	2	DE10200268A1	DE		2002-11-28	Mitsubishi Denki K	к.			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
			NON-PATER	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and or country where published.									
	1									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EYAMINED CIONATIDE										

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

See find Code of USPTO Petert Documents at swee USPTO.COM or MPEP 901.04. Either distinct that asseed the document, by the how letter GWIPO Standard ST3.) "For Supassee peterfor document, the production of the year of the region or the Empirery amengerates one see and under the Operation as an indicated on the document by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. Speciation is to place a check mark here if English targuages threatistics as standards.

Examiner Signature

Application Number Filing Date Filing Date Filing Date Filing Marked Inventor Robert-Christian Hagen Art Unit Examiner Name Attorney Docket Number | M31.175.101/FINSS2PCT/US

CERTIFICATION STATEMENT

Please see	37	CFR 1	.97	and 1	.98	to	make	the	appropriate	selection(s):
------------	----	-------	-----	-------	-----	----	------	-----	-------------	------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI.)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Steven E. Dicke/	Date (YYYY-MM-DD)	2006-08-31
Name/Drint	Stoven E Dicke	Registration Number	38 //31

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.